Mark T. Hamann, PhD, Principal Investigator
Dr. Mark T. Hamann serves as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery, Biomedical Sciences and Public Health at the MUSC Colleges of Pharmacy and Medicine and also holds Adjunct appointments with The University of Maryland’s Institute of Marine and Environmental Technology.
Dr. Hamann began his career in cGMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota, and then completed a Ph.D. degree in Organic Chemistry at the University of Hawaii, under the guidance of the late Professor Paul J. Scheuer. During his graduate studies, he discovered the lead anticancer agent, kahalalide F which entered clinical trials with the leadership of the biotech company PharmaMar.
He is committed to the success of Sycamore BioPharma and the strategic replacement of petroleum-based fine chemicals with renewables generated through local and regional agriculture and the type of manufacturing available at the facilities at Sycamore BioPharma. This approach to economic development supports both the local economy as well as the reduction of the countries carbon footprint.